Inhibikase Therapeutics, Inc. (IKT)

NASDAQ: IKT · IEX Real-Time Price · USD

1.870

+0.290 (18.35%)

At close: Apr 24, 2024, 4:00 PM

1.790

-0.080 (-4.28%)

Pre-market: Apr 25, 2024, 8:06 AM EDT

Inhibikase Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	9.17	7.19	40.75	13.95	0.02	0.38
Short-Term Investments	4.09	15.86	0	0	0	0
Cash & Cash Equivalents	13.25	23.05	40.75	13.95	0.02	0.38
Cash Growth	-42.51%	-43.44%	192.04%	75500.11%	-95.14%	-
Receivables	0	0.04	0.11	0	0	0.47
Other Current Assets	0.96	1.28	1.61	0.83	0.02	0.4
Total Current Assets	14.21	24.37	42.47	14.78	0.04	1.25
Property, Plant & Equipment	0.3	0.57	0	0	0	0
Other Long-Term Assets	0	0	0	0	0	1.59
Total Long-Term Assets	0.3	0.57	0	0	0	1.59
Total Assets	14.51	24.94	42.47	14.78	0.04	2.85
Accounts Payable	0.65	1.15	1.09	1.72	1	0.95
Deferred Revenue	0	0	0	2.33	1.43	0.26
Current Debt	0.53	0.15	0.25	0.04	0.1	0.23
Other Current Liabilities	2.26	2.4	2.72	0.63	1.72	2.17
Total Current Liabilities	3.44	3.7	4.05	4.72	4.25	3.62
Long-Term Debt	0	0	0	0.28	0.28	0
Other Long-Term Liabilities	0.09	0.21	0	0	0	0
Total Long-Term Liabilities	0.09	0.21	0	0.28	0.28	0
Total Liabilities	3.53	3.9	4.05	5	4.53	3.62
Total Debt	0.53	0.15	0.25	0.32	0.37	0.23
Debt Growth	264.71%	-41.41%	-21.97%	-14.66%	59.93%	-
Retained Earnings	-66.9	-47.87	-29.82	-15.03	-12.18	-6.46
Comprehensive Income	0	0.1	0	0	0	0
Shareholders' Equity	10.98	21.04	38.42	9.78	-4.49	-0.78
Net Cash / Debt	12.72	22.9	40.5	13.63	-0.36	0.15
Net Cash / Debt Growth	-44.46%	-43.45%	197.05%	-	-	-
Net Cash Per Share	2.39	5.42	13.35	9.96	-0.26	0.11
Working Capital	10.77	20.68	38.42	10.06	-4.22	-2.37
Book Value Per Share	2.06	4.98	12.66	7.15	-3.29	-0.58

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).